The Gene Transfer Vector Core is integrated into multiple cancer projects directed at the study of the disease process, therapy and the development of vaccines. Vector Core staff are active participants in the development of gene transfer technologies in the cancer field. The interaction with multiple investigators from various disciplines allows for cross-fertilization of ideas, technical advancements, and innovations in vector designs. The Vector Core's overall objective is to support investigators in the use of gene transfer technologies, including consultation with the PI and staff, development of novel vectors, collaborative testing of vectors generated for function and purity, and finally routine preparation including quality control. Vector Core staff and investigators are in close contact through all phases of vector design and generation, and serves as both a research and development facility for gene transfer studies, and a service facility for routine vector preparations. As a part of the service the Vector Core will provide purified and concentrated preparations of recombinant adenovirus, adeno-associated virus (AAV), vaccinia, baculovirus and retrovirus (including lentivirus). This facility provides access to standard cell lines, expression plasmids, and stock of recombinant reporter viruses. The main responsibilities of the Core will be: Prepare recombinant vectors;Quality control;Vector dissemination;Maintain a database of vector stocks available for use;Catalogue plasmid database of expression vectors;develop new expression vectors as needed;Develop novel methods for virus production;Assist in the design and development of novel vectors. This facility serves the needs of numerous outside investigators interested in both basic and applied research with gene transfer vectors, and is important for several reasons. First, by keeping abreast of many different gene transfer vectors, approaches, and applications, the scientific expertise of the Vector Core staff is strengthened. Second, serving a broad scope of users improves and fosters inter-collegiate communication with focused efforts at developing improved vectors and delivery methods. Finally, a continuum of new ideas from both outside and within the university, and through our consultants insures that the Holden Comprehensive Cancer Center community has access to, or is aware of, the 'state of the art'.

Public Health Relevance

The ability to manipulate genes plays a central role in research designed to understand genetic factors that impact on carcinogenesis and behavior of malignant cells. The Gene Transfer Vector Core provides this vital service to HCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-14
Application #
8640097
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
14
Fiscal Year
2014
Total Cost
$70,596
Indirect Cost
$28,739
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358
Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408
Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773
Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Atay, Safinur; Wilkey, Daniel W; Milhem, Mohammed et al. (2018) Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers. Mol Cell Proteomics 17:495-515

Showing the most recent 10 out of 1080 publications